We recently published a list of 16 Best Mid Cap Growth Stocks To Buy Now. In this article, we are going to take a look at ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 10, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2024 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Liquidia said a U.S. court determined losses caused by interference from United Therapeutics during the launch of its generic Treprostinil Injection were in excess of $137 million.

United Therapeutics Corporation (UTHR) stock saw a modest uptick, ending the day at $353 which represents a slight increase of $1.67 or 0.48% from the prior close of $351.33. The stock opened at $349.

Dr. Roger Jeffs, Ph.D., Chief Executive Officer of Liquidia, stated: “We are pleased with the court’s decision to find United Therapeutics liable for its interference with the launch of generic ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

United Therapeutics (NASDAQ:UTHR) Corporation's (NASDAQ:UTHR) Chief Financial Officer and Treasurer, James Edgemond, has recently completed a series of transactions involving the company's common ...

View United Therapeutics Corporation (UTHR) current and estimated P/E ratio data provided by Seeking Alpha.

Dr. Roger Jeffs, Ph.D., Chief Executive Officer of Liquidia, stated: “We are pleased with the court’s decision to find United Therapeutics liable for its interference with the launch of ...

Dr. Roger Jeffs, Ph.D., Chief Executive Officer of Liquidia, stated: “We are pleased with the court’s decision to find United Therapeutics liable for its interference with the launch ...